Associations Among Behavior-Related Susceptibility Factors in Porphyria Cutanea Tarda

Clinical Gastroenterology and Hepatology

Volumn 8, Issue 3, 2010, Pages

  Jalil, Sajid ^a   Grady, James J ^a   Lee, Chul ^a   Anderson, Karl E ^a  

^a UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

Alcohol; Hepatitis C; Porphyria

Indexed keywords

CHLOROQUINE; ESTROGEN; HFE PROTEIN; HYDROXYCHLOROQUINE; UROPORPHYRINOGEN DECARBOXYLASE;

ADULT; AGED; ALCOHOL CONSUMPTION; ARTICLE; CIGARETTE SMOKING; CLINICAL FEATURE; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE PREDISPOSITION; ECHOGRAPHY; ENZYME ACTIVITY; ENZYME DEFICIENCY; FATTY LIVER; FEMALE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; LIVER BIOPSY; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; PHLEBOTOMY; PORPHYRIA CUTANEA TARDA; RECURRENT DISEASE; SCORING SYSTEM; TREATMENT RESPONSE;

EID: 77349089994     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2009.11.017     Document Type: Article

References (34)

1. Elder G.H. Porphyria cutanea tarda and related disorders. In: Kadish K.M., Smith K., and Guilard R. (Eds). Porphyrin handbook, part II Vol 14 (2003), Academic Press, San Diego 67-92
2. Gisbert J.P., Garcia-Buey L., Alonso A., et al. Hepatocellular carcinoma risk in patients with porphyria cutanea tarda. Eur J Gastroenterol Hepatol 16 (2004) 689-692
3. Anderson K.E. The porphyrias. In: Boyer T., Wright T., and Manns M. (Eds). Zakim and Boyer's hepatology: a textbook of liver diseases (2006), Elsevier, Philadelphia 1391-1432
4. Sinclair P.R., Gorman N., Walton H.S., et al. CYP1A2 is essential in murine uroporphyria caused by hexachlorobenzene and iron. Toxicol Appl Pharmacol 162 (2000) 60-67
5. Smith A.G., Clothier B., Carthew P., et al. Protection of the Cyp1A2(-/-) null mouse against uroporphyria and hepatic injury following exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin. Toxicol Appl Pharmacol 173 (2001) 89-98
6. Phillips J.D., Bergonia H.A., Reilly C.A., et al. A porphomethene inhibitor of uroporphyrinogen decarboxylase causes porphyria cutanea tarda. Proc Natl Acad Sci U S A 104 (2007) 5079-5084
7. Egger N.G., Goeger D.E., Payne D.A., et al. Porphyria cutanea tarda: multiplicity of risk factors including HFE mutations, hepatitis C, and inherited uroporphyrinogen decarboxylase deficiency. Dig Dis Sci 47 (2002) 419-426
8. Rossmann-Ringdahl I., and Olsson R. Porphyria cutanea tarda in a Swedish population: risk factors and complications. Acta Derm Venereol 85 (2005) 337-341
9. Freiberg M.S., Cabral H.J., Heeren T.C., et al. Alcohol consumption and the prevalence of the Metabolic Syndrome in the US: a cross-sectional analysis of data from the Third National Health and Nutrition Examination Survey. Diabetes Care 27 (2004) 2954-2959
10. Lee D.J., Fleming L.E., Arheart K.L., et al. Smoking rate trends in U.S. occupational groups: the 1987 to 2004 National Health Interview Survey. J Occup Environ Med 49 (2007) 75-81
11. Armstrong G.L., Wasley A., Simard E.P., et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 144 (2006) 705-714
12. Karon J.M., Rosenberg P.S., McQuillan G., et al. Prevalence of HIV infection in the United States, 1984 to 1992. JAMA 276 (1996) 126-131
13. Steinberg K.K., Cogswell M.E., Chang J.C., et al. Prevalence of C282Y and H63D mutations in the hemochromatosis (HFE) gene in the United States. JAMA 285 (2001) 2216-2222
14. Cowie C.C., Rust K.F., Byrd-Holt D.D., et al. Prevalence of diabetes and impaired fasting glucose in adults in the U.S. population: National Health And Nutrition Examination Survey 1999-2002. Diabetes Care 29 (2006) 1263-1268
15. Clark J.M., and Diehl A.M. Defining nonalcoholic fatty liver disease: implications for epidemiologic studies. Gastroenterology 124 (2003) 248-250
16. Bulaj Z.J., Phillips J.D., Ajioka R.S., et al. Hemochromatosis genes and other factors contributing to the pathogenesis of porphyria cutanea tarda. Blood 95 (2000) 1565-1571
17. Chiaverini C., Halimi G., Ouzan D., et al. Porphyria cutanea tarda, C282Y, H63D and S65C HFE gene mutations and hepatitis C infection: a study from southern France. Dermatology 206 (2003) 212-216
18. Fargion S., Piperno A., Cappellini M.D., et al. Hepatitis-C virus and porphyria cutanea tarda - evidence of a strong association. Hepatology 16 (1992) 1322-1326
19. El-Serag H.B., Hampel H., Yeh C., et al. Extrahepatic manifestations of hepatitis C among United States male veterans. Hepatology 36 (2002) 1439-1445
20. Bonkovsky H.L., Lambrecht R.W., and Shan Y. Iron as a co-morbid factor in nonhemochromatotic liver disease. Alcohol 30 (2003) 137-144
21. Gisbert J.P., Garcia-Buey L., Pajares J.M., et al. Prevalence of hepatitis C virus infection in porphyria cutanea tarda: systematic review and meta-analysis. J Hepatol 39 (2003) 620-627
22. Bonkovsky H.L., Poh-Fitzpatrick M., Pimstone N., et al. Porphyria cutanea tarda, hepatitis C, and HFE gene mutations in North America. Hepatology 27 (1998) 1661-1669
23. Nagy Z., Koszo F., Par A., et al. Hemochromatosis (HFE) gene mutations and hepatitis C virus infection as risk factors for porphyria cutanea tarda in Hungarian patients. Liver Int 24 (2004) 16-20
24. Tannapfel A., Stolzel U., Kostler E., et al. C282Y and H63D mutation of the hemochromatosis gene in German porphyria cutanea tarda patients. Virchows Arch 439 (2001) 1-5
25. Ivanova A., von Ahsen N., Adjarov D., et al. C282Y and H63D mutations in the HFE gene are not associated with porphyria cutanea tarda in Bulgaria. Hepatology 30 (1999) 1531-1532
26. Lamoril J., Andant C., Bogard C., et al. Epidemiology of hepatitis C and G in sporadic and familial porphyria cutanea tarda. Hepatology 27 (1998) 848-852
27. Roberts A.G., Whatley S.D., Nicklin S., et al. The frequency of hemochromatosis-associated alleles is increased in British patients with sporadic porphyria cutanea tarda. Hepatology 25 (1997) 159-161
28. Hussain I., Hepburn N.C., Jones A., et al. The association of hepatitis C viral infection with porphyria cutanea tarda in the Lothian region of Scotland. Clin Exp Dermatol 21 (1996) 283-285
29. Herrero C., Vicente A., Bruguera M., et al. Is hepatitis C virus infection a trigger of porphyria cutanea tarda?. Lancet 341 (1993) 788-789
30. Stuart K.A., Busfield F., Jazwinska E.C., et al. The C282Y mutation in the haemochromatosis gene (HFE) and hepatitis C virus infection are independent cofactors for porphyria cutanea tarda in Australian patients. J Hepatol 28 (1998) 404-409
31. Mendez M., Rossetti M.V., Del C.B.A.M., et al. The role of inherited and acquired factors in the development of porphyria cutanea tarda in the Argentinean population. J Am Acad Dermatol 52 (2005) 417-424
32. Martinelli A.L., Zago M.A., Roselino A.M., et al. Porphyria cutanea tarda in Brazilian patients: association with hemochromatosis C282Y mutation and hepatitis C virus infection. Am J Gastroenterol 95 (2000) 3516-3521
33. Cogswell M.E., Gallagher M.L., Steinberg K.K., et al. HFE genotype and transferrin saturation in the United States. Genet Med 5 (2003) 304-310
34. Acton R.T., Barton J.C., Snively B.M., et al. Geographic and racial/ethnic differences in HFE mutation frequencies in the Hemochromatosis and Iron Overload Screening (HEIRS) Study. Ethn Dis 16 (2006) 815-821